Lucid Diligence Brief: ZipBio licenses its AI-designed GA AAV program to MeiraGTx
Lucid Diligence Brief: ZipBio licenses its AI-designed GA AAV program to…
Lucid Diligence Brief: Galderma resubmits RelabotulinumtoxinA to the FDA
Lucid Diligence Brief: Galderma resubmits RelabotulinumtoxinA to the FDA…
Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen
Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen…
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission Professional audiences…
Lucid Diligence Brief: Formation Bio licenses miR-124 activator FHND5032 from CTFH
Lucid Diligence Brief: Formation Bio licenses miR-124 activator FHND5032 from…
Lucid Diligence Brief: Seamless Therapeutics and Lilly enter gene-writing pact in hearing loss
Lucid Diligence Brief: Seamless Therapeutics and Lilly enter gene-writing pact…
Lucid Diligence Brief: Boehringer Ingelheim and Simcere partner in IBD
Lucid Diligence Brief: Boehringer Ingelheim and Simcere partner in IBD…
Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader
Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader…
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development…
Lucid Diligence Brief: GSK to acquire RAPT Therapeutics
Lucid Diligence Brief: GSK to acquire RAPT Therapeutics Professional audiences…
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…
Lucid Diligence Brief: AstraZeneca to acquire Modella AI
Lucid Diligence Brief: AstraZeneca to acquire Modella AI Professional audiences…